Compare
Alector, Inc. vs LENZ Therapeutics, Inc. vs Scilex Holding Co vs Lineage Cell Therapeutics, Inc.
| Latest fiscal year | Alector, Inc. ALEC | LENZ Therapeutics, Inc. LENZ | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | Lineage Cell Therapeutics, Inc. LCTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $21.05M | $19.09M | $30.25M | $14.56M |
| Revenue growth (YoY) | -79.1% | n/a | -46.5% | +53.2% |
| Gross margin | n/a | n/a | 65.0% (computed) | n/a |
| Operating margin | -741.3% | -477.5% | n/m | -251.6% |
| Net margin | -679.2% | -430.3% | n/m | -436.5% |
| Net income | -$142.93M | -$82.13M | -$374.05M | -$63.53M |
| EPS (Diluted) | -$1.39 | -$2.85 | -$36.48 | -$0.28 |
| Operating cash flow | -$184.03M | -$69.17M | $3.82M | -$18.92M |
| Free cash flow | -$184.07M | -$70.00M | $3.68M | -$19.44M |
| Cash & equivalents | $65.80M | $25.18M | $4.96M | $40.79M |
| Total assets | $293.24M | $305.88M | $364.98M | $112.58M |
| Total liabilities | $262.59M | $21.54M | $576.73M | $69.24M |
| Shareholders' equity | $30.65M | $284.34M | -$207.78M | $43.35M |
| Return on year-end equity | -466.3% | -28.9% | n/a | -146.6% |
| Shares outstanding | 110.36M | 31.34M | 7.03M | 243.12M |
Revenue, most recent five fiscal years
| Fiscal year | Alector, Inc. | LENZ Therapeutics, Inc. | Scilex Holding Co | Lineage Cell Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $21.05M Ended 2025-12-31 | $19.09M Ended 2025-12-31 | n/a | $14.56M Ended 2025-12-31 |
| 1 year earlier | $100.56M Ended 2024-12-31 | $0 Ended 2024-12-31 | n/a | $9.50M Ended 2024-12-31 |
| 2 years earlier | $97.06M Ended 2023-12-31 | n/a | n/a | $8.95M Ended 2023-12-31 |
| 3 years earlier | $133.62M Ended 2022-12-31 | n/a | n/a | $14.70M Ended 2022-12-31 |
| 4 years earlier | $207.09M Ended 2021-12-31 | n/a | n/a | $4.34M Ended 2021-12-31 |